Last reviewed · How we verify
Praxadium (NORDAZEPAM)
Praxadium (generic name: NORDAZEPAM) is a nordazepam drug. It is currently FDA-approved.
At a glance
| Generic name | NORDAZEPAM |
|---|---|
| Drug class | nordazepam |
| Target | Gamma-aminobutyric acid receptor subunit rho-2, Gamma-aminobutyric acid type B receptor subunit 2, GABA-A receptor alpha-1/beta-2/gamma-2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Praxadium CI brief — competitive landscape report
- Praxadium updates RSS · CI watch RSS
Frequently asked questions about Praxadium
What is Praxadium?
Praxadium (NORDAZEPAM) is a nordazepam drug.
What is the generic name of Praxadium?
NORDAZEPAM is the generic (nonproprietary) name of Praxadium.
What drug class is Praxadium in?
Praxadium belongs to the nordazepam class. See all nordazepam drugs at /class/nordazepam.
What development phase is Praxadium in?
Praxadium is FDA-approved (marketed).
What does Praxadium target?
Praxadium targets Gamma-aminobutyric acid receptor subunit rho-2, Gamma-aminobutyric acid type B receptor subunit 2, GABA-A receptor alpha-1/beta-2/gamma-2 and is a nordazepam.
Related
- Drug class: All nordazepam drugs
- Target: All drugs targeting Gamma-aminobutyric acid receptor subunit rho-2, Gamma-aminobutyric acid type B receptor subunit 2, GABA-A receptor alpha-1/beta-2/gamma-2
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing